Natera, Inc. (NTRA): Herm Rosenman , Chief Financial Officer of Natera, Inc. sold 1,824 shares on Jul 6, 2016. The Insider selling transaction was reported by the company on Jul 8, 2016 to the Securities and Exchange Commission. The shares were sold at $12.10 per share for a total value of $22,070.40 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Matthew Rabinowitz (Chief Executive Officer) sold 104,892 shares at $12.12 per share price.On Jun 21, 2016, Roelof Botha (director 10% owner) purchased 837,521 shares at $11.94 per share price.Also, On Jun 21, 2016, Jonathan Sheena (Chief Technology Officer) sold 188,442 shares at $11.94 per share price.On Jun 21, 2016, John Steuart (director) purchased 83,752 shares at $11.94 per share price.
Shares of Natera Inc (NTRA) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.14 points or -1.14% at $12.14 with 1,40,175 shares getting traded. Post opening the session at $12.11, the shares hit an intraday low of $11.94 and an intraday high of $12.28 and the price vacillated in this range throughout the day. The company has a market cap of $622 M and the number of outstanding shares has been calculated to be 5,12,56,216 shares. The 52-week high of Natera Inc is $22.65 and the 52-week low is $6.52.
Company has been under the radar of several Street Analysts.Natera Inc is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 16 from a previous price target of $15 .The Rating was issued on May 23, 2016.Natera Inc is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 15 from a previous price target of $14 .The Rating was issued on May 11, 2016.Natera Inc is Initiated by The Benchmark Company to Buy and the brokerage firm has set the Price Target at $14. The Rating was issued on Apr 19, 2016.
Natera Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening Pre-implantation Genetic Diagnosis Products of Conception Non-Invasive Paternity Testing High Throughput Carrier Screening and Non-Invasive Prenatal Testing.